// App-Quantinova.ai

P57.07 : The Scottish Immunotherapy Prognostic Score (SIPS) Predicts Response to First-Line Pembrolizumab for Metastatic Non-Small Cell Lung Cancer

Researchers

Presenter

  • M. Stares

Principal Investigators

  • T. Ding

  • F. Thomson

  • S. Campbell

  • T. Evans

  • A. Tufail

Medical Centers

  • Medical School, University Of Edinburgh, Edinburgh, UK

  • Edinburgh Cancer Centre, Edinburgh, Scotland/GB

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Non Small Cell Lung cancer

Biomarkers

  • Neutrophil lymphocyte ratio

  • Programmed death-ligand 1

  • Human albumin

Drug/Treatment

  • Pembrolizumab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • N/A

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved